A report published Wednesday in The BMJ questioned the safety and effectiveness of the Alzheimer’s disease drug Kisunla ...

Shares of Eli Lilly & Co. LLY slid 1.65% to $909.32 Thursday, on what proved to be an all-around favorable trading session ...

BioAge Labs stock rallied Thursday on the company's upsized IPO — reflecting enthusiasm for its approach to obesity ...

A woman from Chester Springs, Pennsylvania, is one of the first patients in the country to receive a new FDA-approved ...

Shares of BioAge Labs (BIOA), a biopharmaceutical company focused on obesity drugs, opened 25% above its initial public ...

A study from tirzepatide's manufacturer found that the GLP-1 drug could significantly improve heart failure symptoms.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 600.18% and ...

Thousands of plaintiffs have sued Ozempic manufacturers for failing to warn them about the risk of stomach paralysis.

Delve into the world of radiopharmaceuticals: explore their mechanisms, promising candidates, and the key players driving ...

A startling investigation has revealed a troubling story behind donanemab's approval -- one of questionable data, potential ...

The healthcare company's pivot into a new set of technologies will have many implications for the stock.

The surging popularity of weight-loss drugs, expected to be a $150 billion market by early 2030s, has whetted investor appetite in companies looking to tap into the boom. BioAge priced its offering of ...